Women’s Online Weight and fertility study (WOW2)

It is known that being overweight can sometimes affect fertility and pregnancy. Weight loss may improve fertility and improve outcomes for those who become pregnant. 

In the UK, weight loss medication is available which can be prescribed or purchased privately. Medication includes Liraglutide (Saxenda® Victoza® SkinnyJab® Slim Jab®); Semaglutide (Wegovy®, Ozempic® ; Rybelsus® ); Mounjaro (tirzepatide); Orlistat (Xenical® alli®). There have been no studies of these medications in relation to use before pregnancy and it is recommended that those wishing to become pregnant should stop medications before trying to conceive.  As some weight loss medication can be purchased privately in pharmacies or online, it is not known if people using it are aware of the recommendations regarding delaying pregnancy and use of contraception.

The aim of this study is to understand more about the use of weight loss medications in those with overweight/obesity and its association with fertility and pregnancy intention. We would like to find out what women, aged 18 -45 years, understand about this medication and the acceptability of delaying pregnancy after obesity treatments. This will help us to support people who are trying to lose weight to improve both their health and that of any future children, should they wish to become pregnant. 

We are conducting a survey in women, aged 18-45 years, who are living with overweight/obesity. We are inviting those who have considered using are currently using or have used weight loss medications in the past to take part. 

If you agree to take part in the study, please complete the online questionnaire. The questionnaire takes approximately 10 minutes and asks about you, your use of weight loss medications, your health and lifestyle, your periods, your plans for contraception and pregnancy. To take part please email us at mfresearch@plymouth.ac.uk.

Read the participant information sheet for more information (PDF)